Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28915897 | 0.98 | AKR1C1 (0.66) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| SCHEMBL2384832 | 0.98 | AKR1C1 (0.66) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| SCHEMBL1492737 | 0.96 | AKR1C1 (0.62) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| SCHEMBL2221 | 0.92 | AKR1C1 (0.55) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| SCHEMBL3910628 | 0.90 | AKR1C1 (0.53) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| Water SCHEMBL3910626 | 0.88 | AKR1C1 (0.52) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| SCHEMBL4770404 | 0.86 | HDAC1 (0.53) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| SCHEMBL29134935 | 0.83 | AKR1C1 (0.47) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| SCHEMBL11097640 | 0.83 | AKR1C1 (0.47) | AKR1C1MEN1KMT2ATSHRHDAC1 | |
| SCHEMBL3032228 | 0.83 | AKR1C1 (0.47) | AKR1C1MEN1KMT2ATSHRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521395-B2 | Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2026-01-13 | — | — | US | disclosed |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250241908-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | NINGBO MEISHAN BONDED PORT AREA ZHEJIANG UNITED INVESTMENT MANAGEMENT CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| EP-4055015-B1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-04-02 | — | — | EP | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| CN-118103045-A | Alpha protein kinase 1 inhibitors for the treatment of kawasaki disease | 上海药苑生物科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240109853-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE | TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) | 2024-04-04 | — | — | US | disclosed |
| CN-116670133-A | Alpha protein kinase 1 inhibitors and methods of use | 上海药苑生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-104045625-A | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER | 2014-09-17 | — | — | CN | disclosed |
| EP-2683690-A1 | QUINOLINONE DERIVATIVES | GlaxoSmithKline LLC (US) | 2014-01-15 | — | — | EP | disclosed |
| CN-103517896-A | Quinolinone derivatives | GLAXOSMITHKLINE LLC | 2014-01-15 | — | — | CN | disclosed |
| US-20130345212-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2013153479-A2 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130267493-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012119978-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012082817-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | PHKA1, PHKA2, PHKG1 | AKR1C1 2685/4885MEN1 3234/4885KMT2A 3181/4885 |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTB4R2, LTC4S | AKR1C1 145/4885MEN1 2410/4885KMT2A 1697/4885 |
| US-20240109853-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE | PHKA1, PHKA2, PHKG1 | AKR1C1 1693/4885MEN1 2806/4885KMT2A 2978/4885 |
| US-20250241908-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | PHKA1, PHKA2, PHKG1 | AKR1C1 1104/4885MEN1 3169/4885KMT2A 2582/4885 |
| US-20130345212-A1 | QUINOLINONE DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | AKR1C1 1972/4885MEN1 3687/4885KMT2A 2410/4885 |
| US-20130267493-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PRKAG1, PRKAG3, PRKAG2 | AKR1C1 1257/4885MEN1 4037/4885KMT2A 1740/4885 |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | PHKA1, PHKA2, PHKG1 | AKR1C1 891/4885MEN1 3121/4885KMT2A 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.